Leica Biosystems, a Danaher company and a global leader in digital and anatomic pathology solutions, announces a major expansion of the Aperio  AI Store, reinforcing its momentum as a rapidly growing gateway to a curated menu of leading AI tools, seamlessly embedded in a single interface.  Designed to enhance accuracy, reduce turnaround times, and streamline workflows, Aperio AI Store serves as the gateway to the most innovative  analytics in digital pathology.

Available exclusively through Aperio HALO AP image management system, the Aperio AI Store has quickly gained traction since its US launch in  October 2025, delivering a broad and practical suite of AI tools designed to support pathologists in routine workflows.

The latest expansion introduces five new AI algorithms from existing partners and welcomes Mindpeak as a new partner, further strengthening the  breadth and depth of solutions available from AI innovators including Indica Labs, Deep Bio, Lunit, and Histofy.

Designed as an open-concept, multi-vendor marketplace, the Aperio AI Store brings a wide range of best-in-class digital pathology tools for  operational and workflow improvements to quantitative analysis of complex biomarkers. The single, streamlined interface enables pathologists to  access and leverage multiple AI solutions from different providers, without the burden of navigating separate software systems or viewers.

“With the rapid expansion of the Aperio AI Store and its growing network of leading AI partners, we are making it easier than ever for laboratories  to access powerful AI tools,” said Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems. “By delivering  these capabilities within a single interface, the Aperio AI Store helps pathologists adopt AI in a practical, scalable way that fits naturally into their  existing workflows.”

Visit Leica Biosystems at USCAP booth #223 in San Antonio, TX March 23-25, 2026, to experience Aperio HALO AP IMS and Aperio AI Store, in  addition to our other innovative staining and digital pathology solutions. Join us at our booth on Monday, March 23, at 10:30 AM CDT for our  exciting new product unveiling.

For Research Use Only. Not For Use In Diagnostic Procedures.

About Leica Biosystems

Leica Biosystems is a cancer diagnostics company and a global leader in anatomic and digital pathology solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only  company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step.  The company’s mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of its corporate culture. Leica Biosystems is proud to be a  Danaher Corporation subsidiary.

About Danaher

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human  health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world.  Danaher’s advanced science and technology – and proven ability to innovate – help enable faster, more accurate diagnoses and help reduce the time  and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous  improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while  setting the foundation for a healthier, more sustainable tomorrow.